Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus TRANSDERM SCOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus TRANSDERM SCOP.
ANTIVERT vs TRANSDERM SCOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the vestibular system, gastrointestinal tract, and central nervous system, inhibiting vagal nerve activity and preventing motion-induced nausea and vomiting.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
One transdermal patch (1 mg/72 hours) applied to the hairless area behind the ear at least 4 hours before anticipated exposure; replace every 72 hours as needed.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
The terminal elimination half-life of scopolamine is approximately 9.5 hours (range 6-12 hours) following transdermal administration. In elderly patients, half-life may be prolonged to up to 20 hours.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Scopolamine is extensively metabolized; about 50% of a dose is excreted renally as metabolites and unchanged drug, with less than 10% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 30-40% of the dose.
Category C
Category C
Antiemetic
Antiemetic